非ウイルス性遺伝子導入技術の市場規模、シェア、動向分析レポート：モード別、用途別、最終用途別、地域別、セグメント別予測、2025年～2030年

非ウイルス性遺伝子導入技術市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の非ウイルス性遺伝子導入技術市場規模は2030年までに71億1,000万米ドルに達し、予測期間中の2025～2030年のCAGRは12.29％で成長すると予測されています。

同市場の成長を牽引しているのは、遺伝子治療や研究において、ウイルスベクターに代わる安全でスケーラブルかつ費用対効果の高い代替品に対する需要の高まりです。ウイルス法とは異なり、脂質ナノ粒子（LNP）、ポリマー、エレクトロポレーションなどの非ウイルス技術は、免疫原性が低く、製造の複雑さが軽減されています。これらの特性は、mRNAベースのワクチンやCRISPR/Cas9ベースの遺伝子編集療法など、大規模な応用に非常に適しています。ModernaとPfizer-BioNTechによるmRNA COVID-19ワクチンの成功は、非ウイルス導入システムの可能性をさらに実証し、このセグメントへの世界の投資に拍車をかけた。

ナノ技術と生体材料の進歩は、このセグメントの技術革新をさらに加速させています。ナノ粒子、リポプレックス、ハイブリッドキャリアは、トランスフェクション効率の向上と標的導入のために最適化されつつあります。がん、希少遺伝性疾患、心血管疾患などの慢性疾患の有病率の上昇に伴い、効果的で正確な治療ソリューションに対するニーズが急増しています。大きな遺伝子量を導入し、繰り返し投与できる非ウイルス技術は、こうしたアンメット・メディカル・ニーズに対応する上で極めて重要です。さらに、in vitroでの研究用途とin vivoでの治療用途の両方において汎用性があることから、バイオテクノロジー、製薬会社、学術機関などでの採用が拡大しています。

遺伝子治療研究に対する政府資金や民間投資の増加も市場成長の主要促進要因です。北米や欧州のような地域は研究開発の面でリードしているが、中国やインドのようなアジア太平洋の新興国は、バイオテクノロジーのインフラが整備され、規制の枠組みが整備されつつあるため、急速に進歩しています。さらに、バイオテクノロジー企業と学術機関との提携がイノベーションを促進し、非ウイルス導入ソリューションのアクセシビリティを拡大することで、急速に進化する遺伝子治療セグメントでの関連性が確保されています。

非ウイルス性遺伝子導入技術市場レポートハイライト

• 2024年には化学的セグメントが最大の収益シェアを占め、予測期間中に最も速い成長率を示すと予測されています。非ウイルス性遺伝子導入技術の化学的モードは、効率的で安全かつスケーラブルな遺伝子導入システムに対する需要の高まりが原動力となっています。
• 2024年には、遺伝子機能、発現、制御を調査するための多用途で効率的かつコスト効率の高いツールに対する需要の高まりにより、調査市場が最大の収益シェアを占めました。
• 最終用途別では、研究・学術機関セグメントが2024年に48.11％の最大収益シェアを獲得し、予測期間中に最も速いCAGRが見込まれます。この成長は、遺伝子の機能、発現、修飾を研究するための、信頼性が高く、効率的で、費用対効果の高いアプローチに対する需要の高まりに後押しされています。
• 2024年の市場シェアは41.25%で、北米地域が世界を支配しています。この地域は先進的な医療インフラの恩恵を受けており、革新的な遺伝子導入技術の迅速な導入を可能にしています。精密医療への関心の高まりと、遺伝性疾患に焦点を当てた臨床検査の増加が、市場の成長をさらに後押ししています。さらに、政府の取り組みやゲノム研究への資金援助は、非ウイルス導入技術の利用拡大に寄与しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 産業分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 モードビジネス分析

• モードセグメントダッシュボード
• 非ウイルス性遺伝子導入技術市場：モード変動分析
• 非ウイルス性遺伝子導入技術市場の規模と動向分析、モード別、2018～2030年
• 化学的
  • 化学市場推定・予測、2018～2030年
  • LNP
  • ポリマー
  • その他
• 物理的
  • 2018～2030年の物理市場推定・予測
  • エレクトロポレーション
  • マイクロインジェクション
  • その他

第5章 用途ビジネス分析

• 用途セグメントダッシュボード
• 非ウイルス性遺伝子導入技術市場：用途変動分析
• 非ウイルス性遺伝子導入技術市場の規模と動向分析、用途別、2018～2030年
• 研究
  • 研究市場推定・予測、2018～2030年
• 治療
  • 治療市場推定・予測、2018～2030年
  • 遺伝子治療
  • 細胞療法
  • ワクチン

第6章 最終用途ビジネス分析

• 最終用途セグメントダッシュボード
• 非ウイルス性遺伝子導入技術市場：最終用途変動分析
• 非ウイルス性遺伝子導入技術市場の規模と動向分析、最終用途別、2018～2030年
• バイオテクノロジーとバイオ医薬品企業
  • バイオテクノロジーとバイオ医薬品企業市場推定・予測、2018～2030年
• 研究・学術機関
  • 研究・学術機関市場推定・予測、2018～2030年
• その他
  • その他市場推定・予測、2018～2030年

第7章 モード、アプリケーション、最終用途による地域ビジネス分析

• 地域ダッシュボード
• 市場規模と予測と動向分析、2024年と2030年
• 北米
  • 北米の非ウイルス性遺伝子導入技術市場、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州の非ウイルス性遺伝子導入技術市場、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の非ウイルス性遺伝子導入技術市場、2018～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ラテンアメリカの非ウイルス性遺伝子導入技術市場、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの非ウイルス性遺伝子導入技術市場、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業分類
• 戦略マッピング
• 企業市況分析、2024年
• 企業プロファイル/上場企業
  • Thermo Fisher Scientific Inc.
  • GenScript
  • Danaher
  • Merck KGaA
  • Bio-Rad Laboratories
  • Altogen Biosystems
  • Lonza
  • Sonidel
  • SIRION BIOTECH GmbH
  • Innovative Cell Technologies, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 Global non-viral gene delivery technologies market, by region, 2018 - 2030 (USD Million)
• Table 3 Global non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 4 Global non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 5 Global non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 6 North America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
• Table 7 North America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 8 North America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 9 North America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 10 U.S. Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 11 U.S. Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 12 U.S. Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 13 Canada Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 14 Canada Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 15 Canada Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 16 Mexico Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 17 Mexico Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 18 Mexico Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 19 Europe Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 21 Europe Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 22 Europe Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 23 Germany Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 24 Germany Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 25 Germany Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 26 UK Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 27 UK Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 28 UK Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 29 France Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 30 France Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 31 France Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 32 Italy Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 33 Italy Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 34 Italy Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 35 Spain Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 36 Spain Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 37 Spain Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 38 Denmark Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 39 Denmark Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 40 Denmark Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 41 Sweden Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 42 Sweden Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 43 Sweden Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 44 Norway Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 45 Norway Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 46 Norway Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 51 China Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 52 China Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 53 China Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 54 Japan Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 55 Japan Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 56 Japan Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 57 India Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 58 India Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 59 India Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 60 South Korea Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 61 South Korea Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 62 South Korea Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 63 Australia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 64 Australia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 65 Australia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 66 Thailand Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 67 Thailand Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 68 Thailand Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 69 Latin America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 71 Latin America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 72 Latin America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 73 Brazil Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 74 Brazil Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 75 Brazil Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 76 Argentina Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 77 Argentina Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 78 Argentina Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 79 Middel East & Africa Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 83 South Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 84 South Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 85 South Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 89 UAE Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 90 UAE Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 91 UAE Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
• Table 92 Kuwait Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
• Table 93 Kuwait Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
• Table 94 Kuwait Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Market formulation & validation
• Fig. 6 Non-viral gene delivery technologies market: market outlook
• Fig. 7 Laser capture microdissection competitive insights
• Fig. 8 Parent market outlook
• Fig. 9 Non-viral gene delivery technologies market driver impact
• Fig. 10 Non-viral gene delivery technologies market restraint impact
• Fig. 11 Non-viral gene delivery technologies market: Mode movement analysis
• Fig. 12 Non-viral gene delivery technologies market: Mode outlook and key takeaways
• Fig. 13 Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Physical market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 16 Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 17 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Non-viral gene delivery technologies market: Application movement analysis
• Fig. 22 Non-viral gene delivery technologies market: Application outlook and key takeaways
• Fig. 23 Research market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Gene Therapy market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 26 Cell Therapy market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 27 Vaccines market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 28 Non-viral gene delivery technologies market: End use movement analysis
• Fig. 29 Non-viral gene delivery technologies market: End use outlook and key takeaways
• Fig. 30 Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 33 North America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 U.S. non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Canada non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Mexico non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Europe non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 UK non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Germany non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 France non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Italy non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Spain non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Denmark non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Sweden non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Norway non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Asia Pacific Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 China non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Japan non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 India non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Thailand non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 South Korea Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Australia non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Latin America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Brazil Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Argentina Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Middle East and Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 South Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 UAE Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Kuwait Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)

Non-viral Gene Delivery Technologies Market Growth & Trends:

The global non-viral gene delivery technologies market size is anticipated to reach USD 7.11 billion by 2030 and grow at a CAGR of 12.29% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is driven by the growing demand for safe, scalable, and cost-effective alternatives to viral vectors in gene therapy and research. Unlike viral methods, non-viral technologies such as lipid nanoparticles (LNPs), polymers, and electroporation offer lower immunogenicity and reduced manufacturing complexities. These attributes make them highly suitable for large-scale applications, including mRNA-based vaccines and CRISPR/Cas9-based gene editing therapies. The success of mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech further validated the potential of non-viral delivery systems, spurring global investment in this sector.

Advancements in nanotechnology and biomaterials are further accelerating innovation in the field. Nanoparticles, lipoplexes, and hybrid carriers are being optimized for enhanced transfection efficiency and targeted delivery. With the rising prevalence of chronic diseases, including cancer, rare genetic disorders, and cardiovascular conditions, the need for effective and precise therapeutic solutions has surged. Non-viral technologies, with their ability to deliver large genetic payloads and support repeat administrations, are pivotal in addressing these unmet medical needs. In addition, their versatility in both in vitro research applications and in vivo therapeutic use cases expands their adoption across biotechnology, pharmaceutical companies, and academic institutes.

The rising government funding and private investments in gene therapy research are also key drivers of market growth. Regions like North America and Europe lead in terms of R&D, but emerging economies in Asia-Pacific, such as China and India, are rapidly advancing due to increasing biotech infrastructure and supportive regulatory frameworks. Furthermore, partnerships between biotech companies and academic institutions are fostering innovation and expanding the accessibility of non-viral delivery solutions, ensuring their relevance in the rapidly evolving field of gene therapy.

Non-viral Gene Delivery Technologies Market Report Highlights:

• The chemical segment accounted for the largest revenue share in 2024 and is projected to witness the fastest growth rate over the forecast period. The chemical mode of non-viral gene delivery technologies is driven by the increasing demand for efficient, safe, and scalable gene delivery systems.
• In 2024, research dominated the market with the largest revenue share, driven by the increasing demand for versatile, efficient, and cost-effective tools to investigate gene function, expression, and regulation.
• By end use, the research and academic institutes segment captured the largest revenue share of 48.11% in 2024 and is expected to experience the fastest CAGR during the forecast period. This growth is fueled by the rising demand for reliable, efficient, and cost-effective approaches to study gene function, expression, and modification.
• The North American region dominated globally with a market share of 41.25% in 2024. The region benefits from advanced healthcare infrastructure, enabling the rapid adoption of innovative gene delivery techniques. Growing interest in precision medicine and increasing clinical trials focused on genetic disorders further boost market growth. In addition, government initiatives and funding for genomic research contribute to the expanding use of non-viral delivery technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Mode Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Adoption in Therapeutics and Research
    • 3.2.1.2. Technological Advancements and Innovation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited Delivery Efficiency for Complex Targets
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Mode Business Analysis

• 4.1. Mode Segment Dashboard
• 4.2. Non-viral gene delivery technologies market: Mode Movement Analysis
• 4.3. Non-viral gene delivery technologies market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
• 4.4. Chemical
  • 4.4.1. Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. LNPs
    • 4.4.2.1. LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Polymers
    • 4.4.3.1. Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Physical
  • 4.5.1. Physical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Electroporation
    • 4.5.2.1. Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Microinjection
    • 4.5.3.1. Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Non-viral gene delivery technologies market Application Movement Analysis
• 5.3. Non-viral gene delivery technologies market Size & Trend Analysis, by mode, 2018 to 2030 (USD Million)
• 5.4. Research
  • 5.4.1. Research market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Therapeutics
  • 5.5.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Gene Therapy
    • 5.5.2.1. Gene Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Cell Therapy
    • 5.5.3.1. Cell Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Vaccines
    • 5.5.4.1. Vaccines market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Non-viral gene delivery technologies market End Use Movement Analysis
• 6.3. Non-viral gene delivery technologies market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Biotechnology and Biopharmaceutical Companies
  • 6.4.1. Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Research and academic institutes
  • 6.5.1. Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by mode, application, end use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
• 7.3. North America
  • 7.3.1. North America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait non-viral gene delivery technologies market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. GenScript
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Danaher
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Merck KGaA
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Bio-Rad Laboratories
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Altogen Biosystems
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Lonza
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Sonidel
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. SIRION BIOTECH GmbH
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Innovative Cell Technologies, Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives